Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

7.5%

3 terminated out of 40 trials

Success Rate

82.4%

-4.1% vs benchmark

Late-Stage Pipeline

30%

12 trials in Phase 3/4

Results Transparency

21%

3 of 14 completed with results

Key Signals

3 with results82% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (8)
P 1 (1)
P 2 (3)
P 3 (8)
P 4 (4)

Trial Status

Completed14
Unknown9
Recruiting7
Terminated3
Active Not Recruiting3
Enrolling By Invitation2

Trial Success Rate

82.4%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT05325008Phase 3Recruiting

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

NCT03924219Completed

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

NCT05224583Enrolling By Invitation

Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

NCT05708508Phase 3RecruitingPrimary

Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients

NCT07407673Phase 2Not Yet RecruitingPrimary

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation

NCT06219616Not ApplicableCompletedPrimary

Prediction of BK Virus Reactivation in Kidney Transplant Recipient

NCT04542733Not ApplicableRecruitingPrimary

The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient

NCT06407232Phase 3Recruiting

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

NCT04815954Not ApplicableActive Not Recruiting

Early vs Late Urinary Catheter Removal After Renal Transplantation

NCT05708534RecruitingPrimary

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

NCT05836636Active Not RecruitingPrimary

Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study

NCT06825117Not ApplicableEnrolling By Invitation

PRObiotics for KIdney Transplantation

NCT05042076Phase 1CompletedPrimary

BK With VST for Kidney Transplant Patients

NCT04494776Recruiting

SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study

NCT04701528Phase 2Completed

Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients

NCT05597540Phase 3Recruiting

Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

NCT02263703Phase 3Completed

Immunogenicity of HPV Vaccine in Immunosuppressed Children

NCT06364618Not Yet RecruitingPrimary

Use of Wearables to Detect Infections in Kidney Transplant Recipients

NCT01353339Phase 4Completed

Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study

NCT04747522Active Not RecruitingPrimary

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)

Scroll to load more

Research Network

Activity Timeline